Skip to main content
PRGO
NYSE Life Sciences

Perrigo Finalizes Interim CEO Compensation with $2.5M RSU Grant

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Pharmaceutical Stocks · Healthcare
Sentiment info
Neutral
Importance info
7
Price
$11.09
Mkt Cap
$1.534B
52W Low
$9.225
52W High
$28.435
52W Position info
20% above low
Off High info
61% below high
Rel. Volume info
0.8× avg
Market data snapshot near publication time

PRGO sits 20% above its 52-week low of $9.225.

Summary

Perrigo has disclosed the compensation package for its Interim President and CEO, Albert A. Manzone, including a $1.27 million annual salary and a $2.5 million restricted stock unit grant.


Key Events · Executive and Board Changes · PRGO

  • Interim CEO Compensation Finalized

    Perrigo has disclosed the definitive compensatory arrangements for Albert A. Manzone, who was appointed Interim President and Chief Executive Officer on June 7, 2026.

  • Substantial Equity Grant Awarded

    Mr. Manzone will receive a one-time special restricted stock unit (RSU) grant with a grant-date fair value of $2.5 million, vesting upon the earlier of one year, the hiring of a permanent CEO, or a change of control.

  • Fixed Term and Base Salary

    The interim employment agreement is for a fixed term from June 7, 2026, to December 31, 2026, with an annual base salary of $1.27 million.

  • Performance-Based Cash Bonus

    A one-time cash bonus of $250,000 is included, subject to performance metrics approved by the board of directors.


Analysis · PRGO · Life Sciences

This amendment provides the full compensation details for Albert A. Manzone, who was appointed Interim President and CEO following the previous CEO's resignation. The package includes a $1.27 million annual base salary, a $250,000 performance bonus, and a significant $2.5 million restricted stock unit grant. These terms are important for understanding the company's leadership costs during a period of transition and financial challenges, especially after a recent CEO departure due to personal conduct and a substantial Q1 net loss.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, PRGO was trading at $11.09 on NYSE in the Life Sciences sector, with a market capitalization of approximately $1.5B. The 52-week trading range was $9.23 to $28.44. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

PRGO - Latest Insights

PRGO
Nov 04, 2026, 12:54 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $16.47
Real-time Price: $15.94 info
Change: -$0.525 (-3%) info
Market Cap: $2.213B info
PRGO
Nov 04, 2026, 6:44 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $16.15
Real-time Price: $15.94 info
Change: -$0.210 (-1%) info
Market Cap: $2.213B info
PRGO
Nov 04, 2026, 6:41 AM EST
Source: Reuters
Importance Score:
7
Price at Filing: $16.15
Real-time Price: $15.94 info
Change: -$0.210 (-1%) info
Market Cap: $2.213B info
PRGO
Nov 04, 2026, 6:30 AM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $15.70
Real-time Price: $15.94 info
Change: +$0.240 (+2%) info
Market Cap: $2.213B info
PRGO
Oct 29, 2026, 9:01 AM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $15.95
Real-time Price: $15.94 info
Change: -$0.0100 (-0.06%) info
Market Cap: $2.213B info